Sexually transmitted infections among HIV-1-discordant couples

Brandon L Guthrie, James N Kiarie, Susan Morrison, Grace C John-Stewart, John Kinuthia, William L H Whittington, Carey Farquhar, Brandon L Guthrie, James N Kiarie, Susan Morrison, Grace C John-Stewart, John Kinuthia, William L H Whittington, Carey Farquhar

Abstract

Introduction: More new HIV-1 infections occur within stable HIV-1-discordant couples than in any other group in Africa, and sexually transmitted infections (STIs) may increase transmission risk among discordant couples, accounting for a large proportion of new HIV-1 infections. Understanding correlates of STIs among discordant couples will aid in optimizing interventions to prevent HIV-1 transmission in these couples.

Methods: HIV-1-discordant couples in which HIV-1-infected partners were HSV-2-seropositive were tested for syphilis, chlamydia, gonorrhea, and trichomoniasis, and HIV-1-uninfected partners were tested for HSV-2. We assessed sociodemographic, behavioral, and biological correlates of a current STI.

Results: Of 416 couples enrolled, 16% were affected by a treatable STI, and among these both partners were infected in 17% of couples. A treatable STI was found in 46 (11%) females and 30 (7%) males. The most prevalent infections were trichomoniasis (5.9%) and syphilis (2.6%). Participants were 5.9-fold more likely to have an STI if their partner had an STI (P<0.01), and STIs were more common among those reporting any unprotected sex (OR = 2.43; P<0.01) and those with low education (OR = 3.00; P<0.01). Among HIV-1-uninfected participants with an HSV-2-seropositive partner, females were significantly more likely to be HSV-2-seropositive than males (78% versus 50%, P<0.01).

Conclusions: Treatable STIs were common among HIV-1-discordant couples and the majority of couples affected by an STI were discordant for the STI, with relatively high HSV-2 discordance. Awareness of STI correlates and treatment of both partners may reduce HIV-1 transmission.

Trial registration: ClinicalTrials.gov NCT00194519.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Concordance of treatable STIs identified…
Figure 1. Concordance of treatable STIs identified in female and male partners.
Slices of the pie represent the proportion of couples affected and unaffected by an STI. The sections of the upper bar represent the proportion of affected couples in which both partners were infected with an STI, only the female was infected, and only the male was infected.

References

    1. Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368:531–536.
    1. Bunnell R, Ekwaru JP, Solberg P, Wamai N, Bikaako-Kajura W, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS. 2006;20:85–92.
    1. Auvert B, Males S, Puren A, Taljaard D, Carael M, et al. Can highly active antiretroviral therapy reduce the spread of HIV?: A study in a township of South Africa. J Acquir Immune Defic Syndr. 2004;36:613–621.
    1. Baggaley RF, Ferguson NM, Garnett GP. The epidemiological impact of antiretroviral use predicted by mathematical models: a review. Emerg Themes Epidemiol. 2005;2:9.
    1. Gray RH, Li X, Wawer MJ, Gange SJ, Serwadda D, et al. Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS. 2003;17:1941–1951.
    1. UNAIDS . Geneva, Switzerland: WHO.; 2007. AIDS epidemic update: December 2007.50
    1. Baryarama F, Bunnell R, McFarland W, Hudes ES, Neilands TB, et al. Estimating HIV incidence in voluntary counseling and testing clients in Uganda (1992–2003). J Acquir Immune Defic Syndr. 2007;44:99–105.
    1. Lingappa JR, Lambdin B, Bukusi EA, Ngure K, Kavuma L, et al. Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS ONE. 2008;3:e1411.
    1. Were WA, Mermin JH, Wamai N, Awor AC, Bechange S, et al. Undiagnosed HIV infection and couple HIV discordance among household members of HIV-infected people receiving antiretroviral therapy in Uganda. J Acquir Immune Defic Syndr. 2006;43:91–95.
    1. Robinson NJ, Mulder D, Auvert B, Whitworth J, Hayes R. Type of partnership and heterosexual spread of HIV infection in rural Uganda: results from simulation modelling. Int J STD AIDS. 1999;10:718–725.
    1. Dunkle KL, Stephenson R, Karita E, Chomba E, Kayitenkore K, et al. New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet. 2008;371:2183–2191.
    1. UNAIDS . Geneva: UNAIDS.; 2005. AIDS epidemic update: December 2005.98
    1. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191:1403–1409.
    1. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect. 1999;75:3–17.
    1. Cohen MS. Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. Lancet. 1998;351(Suppl 3):5–7.
    1. Abu-Raddad LJ, Magaret AS, Celum C, Wald A, Longini IM,, Jr., et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS ONE. 2008;3:e2230.
    1. Laga M, Manoka A, Kivuvu M, Malele B, Tuliza M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS. 1993;7:95–102.
    1. McClelland RS, Sangare L, Hassan WM, Lavreys L, Mandaliya K, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis. 2007;195:698–702.
    1. Wang CC, McClelland RS, Reilly M, Overbaugh J, Emery SR, et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis. 2001;183:1017–1022.
    1. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis. 2002;185:45–52.
    1. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006;20:73–83.
    1. Hira SK, Feldblum PJ, Kamanga J, Mukelabai G, Weir SS, et al. Condom and nonoxynol-9 use and the incidence of HIV infection in serodiscordant couples in Zambia. Int J STD AIDS. 1997;8:243–250.
    1. Plummer FA, Simonsen JN, Cameron DW, Ndinya-Achola JO, Kreiss JK, et al. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J Infect Dis. 1991;163:233–239.
    1. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921–929.
    1. Cohen MS, Hoffman IF, Royce RA, Kazembe P, Dyer JR, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet. 1997;349:1868–1873.
    1. Ghys PD, Fransen K, Diallo MO, Ettiegne-Traore V, Coulibaly IM, et al. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d'Ivoire. AIDS. 1997;11:F85–93.
    1. Grosskurth H, Mosha F, Todd J, Mwijarubi E, Klokke A, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet. 1995;346:530–536.
    1. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Paxton L, et al. A randomized, community trial of intensive sexually transmitted disease control for AIDS prevention, Rakai, Uganda. AIDS. 1998;12:1211–1225.
    1. Kamali A, Quigley M, Nakiyingi J, Kinsman J, Kengeya-Kayondo J, et al. Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet. 2003;361:645–652.
    1. Sangani P, Rutherford G, Wilkinson D. Population-based interventions for reducing sexually transmitted infections, including HIV infection. Cochrane Database Syst Rev. 2004:CD001220.
    1. Golden MR, Ashley-Morrow R, Swenson P, Hogrefe WR, Handsfield HH, et al. Herpes simplex virus type 2 (HSV-2) Western blot confirmatory testing among men testing positive for HSV-2 using the focus enzyme-linked immunosorbent assay in a sexually transmitted disease clinic. Sex Transm Dis. 2005;32:771–777.
    1. Ashley RL, Militoni J, Lee F, Nahmias A, Corey L. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol. 1988;26:662–667.
    1. Huppert JS, Mortensen JE, Reed JL, Kahn JA, Rich KD, et al. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clin Infect Dis. 2007;45:194–198.
    1. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Sciety Series B (Methodological) 1995;57:289–300.
    1. Kissinger P, Secor WE, Leichliter JS, Clark RA, Schmidt N, et al. Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women. Clin Infect Dis. 2008;46:994–999.
    1. WHO . Geneva: World Health Organization.; 2005. Sexually transmitted and other reproductive tract infections: A guide to essential practice.191
    1. Klinger EV, Kapiga SH, Sam NE, Aboud S, Chen CY, et al. A Community-based study of risk factors for Trichomonas vaginalis infection among women and their male partners in Moshi urban district, northern Tanzania. Sex Transm Dis. 2006;33:712–718.
    1. Mason PR, Fiori PL, Cappuccinelli P, Rappelli P, Gregson S. Seroepidemiology of Trichomonas vaginalis in rural women in Zimbabwe and patterns of association with HIV infection. Epidemiol Infect. 2005;133:315–323.
    1. Buve A, Weiss HA, Laga M, Van Dyck E, Musonda R, et al. The epidemiology of trichomoniasis in women in four African cities. AIDS. 2001;15(Suppl 4):S89–96.
    1. Painter TM. Voluntary counseling and testing for couples: a high-leverage intervention for HIV/AIDS prevention in sub-Saharan Africa. Soc Sci Med. 2001;53:1397–1411.
    1. Desgrees-du-Lou A, Orne-Gliemann J. Couple-centred testing and counselling for HIV serodiscordant heterosexual couples in sub-Saharan Africa. Reprod Health Matters. 2008;16:151–161.
    1. Kamenga M, Ryder RW, Jingu M, Mbuyi N, Mbu L, et al. Evidence of marked sexual behavior change associated with low HIV-1 seroconversion in 149 married couples with discordant HIV-1 serostatus: experience at an HIV counselling center in Zaire. AIDS. 1991;5:61–67.
    1. Allen S, Karita E, Chomba E, Roth DL, Telfair J, et al. Promotion of couples' voluntary counselling and testing for HIV through influential networks in two African capital cities. BMC Public Health. 2007;7:349.
    1. Chomba E, Allen S, Kanweka W, Tichacek A, Cox G, et al. Evolution of couples' voluntary counseling and testing for HIV in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2008;47:108–115.
    1. The Voluntary HIV-1 Counseling and Testing Efficacy Study Group. Efficacy of voluntary HIV-1 counselling and testing in individuals and couples in Kenya, Tanzania, and Trinidad: a randomised trial. Lancet. 2000;356:103–112.
    1. Farquhar C, Kiarie JN, Richardson BA, Kabura MN, John FN, et al. Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmission. J Acquir Immune Defic Syndr. 2004;37:1620–1626.
    1. Maman S, Mbwambo JK, Hogan NM, Weiss E, Kilonzo GP, et al. High rates and positive outcomes of HIV-serostatus disclosure to sexual partners: reasons for cautious optimism from a voluntary counseling and testing clinic in Dar es Salaam, Tanzania. AIDS Behav. 2003;7:373–382.
    1. Butler DM, Smith DM, Cachay ER, Hightower GK, Nugent CT, et al. Herpes simplex virus 2 serostatus and viral loads of HIV-1 in blood and semen as risk factors for HIV transmission among men who have sex with men. AIDS. 2008;22:1667–1671.
    1. Corey L, Wald A, Patel R, Sacks SL, Tyring SK, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004;350:11–20.
    1. Celum C, Wald A, Hughes J, Sanchez J, Reid S, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:2109–2119.
    1. Wald A, Krantz E, Selke S, Lairson E, Morrow RA, et al. Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition. J Infect Dis. 2006;194:42–52.
    1. Weiss HA, Buve A, Robinson NJ, Van Dyck E, Kahindo M, et al. The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. AIDS. 2001;15(Suppl 4):S97–108.
    1. Abu-Raddad LJ, Longini IM,, Jr. No HIV stage is dominant in driving the HIV epidemic in sub-Saharan Africa. AIDS. 2008;22:1055–1061.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться